Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990452 | 1.00 | PARP1 (0.54) | PARP1NR1H2USP2SMN1; SMN2CTSK | |
| SCHEMBL1994122 | 1.00 | PARP1 (0.54) | PARP1NR1H2USP2SMN1; SMN2CTSK | |
| Piperazine SCHEMBL28135831 | 0.98 | PARP1 (0.53) | PARP1NR1H2USP2SMN1; SMN2CTSK | |
| SCHEMBL31172939 | 0.91 | PARP1 (0.49) | PARP1NR1H2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL1283375 | 0.88 | PARP1 (0.52) | PARP1NR1H2USP2SMN1; SMN2CTSK | |
| SCHEMBL4856306 | 0.88 | PARP1 (0.52) | PARP1NR1H2USP2SMN1; SMN2CTSK | |
| SCHEMBL8117710 | 0.88 | PARP1 (0.52) | PARP1NR1H2USP2SMN1; SMN2CTSK | |
| SCHEMBL336578 | 0.88 | PARP1 (0.54) | PARP1USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL336577 | 0.88 | PARP1 (0.54) | PARP1USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL337351 | 0.88 | PARP1 (0.54) | PARP1USP2SMN1; SMN2CTSKHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251211-B | Quinolone carboxylic acid compound and intermediate thereof, preparation method and application | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2025-03-07 | — | — | CN | claimed |
| EP-4504777-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | claimed |
| WO-2023194583-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2023-10-12 | — | — | WO | claimed |
| CN-111285793-B | Fluorine-substituted bimolecular carbazole derivative, and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2022-04-22 | — | — | CN | claimed |
| CN-111285793-A | Fluorine-substituted bimolecular carbazole derivative, and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2020-06-16 | — | — | CN | claimed |
| CN-111217741-A | Fluorine-substituted monocarbazole derivative, preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2020-06-02 | — | — | CN | claimed |
| CN-106674254-B | Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof | 广东省中医院 | 2019-03-15 | — | — | CN | claimed |
| CN-109251211-A | A kind of quinolonecarboxylic acid compound and its intermediate, preparation method and application | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2019-01-22 | — | — | CN | claimed |
| CN-106674254-A | Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof | 广东省中医院 | 2017-05-17 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| EP-2694513-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-02-12 | — | — | EP | claimed |
| WO-2012131633-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-04 | — | — | WO | claimed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-101679275-A | New compounds 707 and their uses | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |